NFKB1 and peripheral neuropathy: This TLR4 signaling regulates chemotherapy-induced peripheral neuropathy in mice (Li et al., 2014; Park et al., 2014), and in the current work, cisplatin related chemotherapy-induced loss of motor dysfunction is ameliorated using αvβ3 integrin receptor antagonist to inhibit NF-kB activation and inflammation.